This trial is evaluating whether DAS181 COVID-19 will improve 1 primary outcome and 16 secondary outcomes in patients with COVID-19. Measurement will happen over the course of Day 14.
This trial requires 274 total participants across 6 different treatment groups
This trial involves 6 different treatments. DAS181 COVID-19 is the primary treatment being studied. Participants will be divided into 4 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
Findings from a recent study has quantified the potential effect of an infection or a vaccination on the U.S. burden of disease, and estimated the potential burden of infection or vaccination with regard to key indicators associated with mortality and health-care burden. A total of 14.7 million new symptomatic infections are estimated to occur annually, primarily in young people and the elderly. The most salient indicator is pneumonia, which leads to 8.3 million hospital stays each year. In contrast, vaccines and antiviral agents can be expected to reduce the number of cases by a considerable degree.
As of May 2, 2020, there are few proven therapeutics for covid-19. Therapies can be grouped in four categories: (1) antiviral drugs (NS5B inhibitors); (2) antivirals (nonnucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs)), (3) immune augmentation, and (4) other medications. Clinical trials of these treatments are not yet ongoing. A Cochrane review will be published soon as new data become available.
Symptoms to look for are fever, fatigue, dry cough and shortness of breath. The symptoms are similar to seasonal influenza. It should not be overlooked as a possible disease causing a significant burden on healthcare services.
The number of cases of coronavirus disease (COVID-19) has risen dramatically in China since November 2019. The increase in these two conditions is linked to a sudden influx of cases. It is most likely due to increased interaction between the general population and infected patients. Prevention of the spread of the disease is essential by limiting the contacts between infected patients and the general population or by isolating patients with serious condition. It can involve measures such as disinfectants and physical barriers. It can also include a massive media campaign and a well-prepared, robust health service. Vaccination should take place as soon as possible in order to decrease the transmission of the virus.
There are several underlying causes of Covid-19 infection in the general population, including demographic, anatomical, social and lifestyle attributes. Some are easily preventable and others not so. It is unlikely that any single factor explains the complexity and dynamics at work in the genesis of the disease.
Overall, this study suggests that Das181 covid-19 decreased both physical pain and general mental distress for those with a confirmed diagnosis of covid-19 and could have a negative impact on a person's ability to engage socially and economically. Overall, it was found that Das181 covid-19 could play a significant role as an adjunct therapy for the management of symptoms of those with (possibly) covid-19. Results from a recent clinical trial suggests that Das181 may have a role in the future to reduce the negative impact of pain, mental distress and loss of productivity, in a manner that increases patient empowerment and quality of life.
Das181 is a very safe and convenient HIV antibody screen. It is a potential candidate blood test for the development of a more diagnostic test for Ebola virus disease, such as a real-time point-of-care PCR test.
The majority of reported cases, however, only have mild/slight symptom profiles. More serious manifestations are rare and are usually caused by underlying medical conditions. These manifestations may include pneumonia, acute respiratory distress syndrome (ARDS), and/or severe neurological complications. At present, it is unknown if these serious clinical outcomes occur more often or less often in people with comorbid conditions (e.g.
If patients present with fever or pain in addition to one or more of the symptoms listed above, it should be strongly felt by medical professionals that patients should receive rapid diagnostics testing in order to prevent further worsening and death of patients, especially those suffering from underlying co-morbidities. A rapid, targeted screening strategy, including targeted tests in patients with higher risk stratification, is needed to prevent further spread of infection.
In the absence of das181, the mutant virus failed to replicate in a cell line derived from the lung of a diseased human donor (hDL2), but can produce a milder phenotype in cell lines derived from donors from a control control lung (hDL10). Since the human lung is an important site of infection, our findings have implications for the pathogenesis of disease in das181-infected patients.
Findings from a recent study provides further support to the use of DAS181 as a treatment and intervention for the disease. Clinical trials investigating multiple dosages/doses, das181 combinations with other investigational coronaviruses should be considered.